Table 1 Procedural characteristics of CVVHDF
Category | Product information |
|---|---|
Device | |
Equipment | Baxter Prismaflex system (Meyzieu Cedex, France) |
Blood filter and extracorporeal circulation circuit | Baxter Prismaflex M150 set (Meyzieu Cedex, France) |
Vascular access | |
Type | Temporary catheter in right internal jugular vein or right femoral vein |
Catheter | Able 12 Fr-16/20-cm double-lumen central venous catheter (Foshan, Guangdong) |
Anticoagulants | |
Drug | Low-molecular-weight heparin |
First dose (IU) | 3000 (2500–4750) |
Additional dose (IU/h) | 158 (100–200) |
Liquid piercing | 0.9% sodium chloride injection 2000 mL |
Blood flow rate (mL/min) | 160 (150–200) |
Dialysate or substitution fluid | Qingshan Likang 4000 mL/bag (Chengdu, China) |
Dialysate flow rate (mL/h) | 1000 |
Substitution method | Combined predilution and postdilution |
Predilution fluid flow rate (ml/h) | 2000 (1000–2250) |
Postdilution fluid flow rate (ml/h) | 1000 (750–1500) |
Duration of single treatment (h) | 16 (10–22) |
Number of CVVHDF sessions | |
2 | 5 (56%) |
3 | 4 (44%) |
Total number of treatments | 22 |
Average number of treatments per patient | 2.44 |